Mannkind (MNKD) Current Deferred Tax Assets (2011 - 2012)
Mannkind (MNKD) posted quarterly Current Deferred Tax Assets of $784.6 million for Q4 2012, up 9.25% year-over-year from $718.2 million in Q1 2012, and up 9.25% quarter-over-quarter from $718.2 million in Q4 2011.
Mannkind (MNKD) Current Deferred Tax Assets (2011 - 2012) Analysis & Trends
Mannkind (MNKD) has reported Current Deferred Tax Assets for 2 consecutive years, with $784.6 million the latest figure, recorded in Q4 2012.
- In Q4 2012, Current Deferred Tax Assets rose 9.25% year-over-year to $784.6 million; the TTM figure through Dec 2012 stood at $784.6 million (up 9.25% YoY), while the FY2012 annual figure was $784.6 million, up 9.25% from the prior year.
- Current Deferred Tax Assets grew to $784.6 million in Q4 2012 per MNKD's latest filing, from $718.2 million in the prior quarter.
- Across five years, Current Deferred Tax Assets topped out at $784.6 million in Q4 2012 and bottomed at $718.2 million in Q4 2011.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Mannkind | 1.19 Bn | 1.08 Bn | 94.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2012 | 784.60 Mn |
| Dec 31, 2012 | 784.60 Mn |
| Dec 31, 2011 | 718.20 Mn |
| Dec 31, 2011 | 718.20 Mn |